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stay of treatment of vascular disease remains elective oper-
ative repair with interposition grafts. Endovascular stents
are an alternative to surgery, although their long-term
results are not yet well defined and problems, such as
endoleaks and restenosis, persist.
There are many different stents available today, manu-
factured in various shapes and materials. Generically, vas-
cular stents can be divided into two types: bare stents and
stent grafts (either with the stent inside or outside the
graft or with anchoring stents at each end of an interposed
graft). The results of such stenting, especially in coronary
arteries, are better than those of angioplasty alone.2 Today,
the vast majority of patients who undergo coronary artery
angioplasty have a stent deployed simultaneously. The
outcome and morphology of peripheral stenting are not as
well defined.
MORPHOLOGIC SEQUENCE OF EVENTS
The long-term clinical efficacy of arterial stenting is
limited by restenosis and systemic complications, which
occur in at least 15% to 30% of patients.1,3 This restenosis
is related to new intimal hyperplasia, likely associated with
mechanical injury to the arterial wall caused by the
endovascular procedure and stent. The sequence of events
leading to restenosis in stented vessels has been studied
retrospectively in human coronary vessels and in experi-
mental animals. A lack of data from human peripheral vas-
cular stents, however, persists, especially sequential
morphologic data.
In human coronary stents, Farb et al3 reported the
morphology of early and late (>30 days) samples.
Immediately after the procedure, small thrombi, primarily
platelets and fibrin, likely start developing and are easily
seen from 1 to 3 days onwards, along with acute inflam-
matory cells. Injury to the media or lipid core penetration
or both increase the inflammatory reaction, whereas stents
in contact with intact fibrous plaque show less inflamma-
tion. At up to 10 to 15 days, thrombi are still seen, along
with some exudation of acute inflammatory cells, invari-
ably around stent struts. The existing intima, especially the
lipid-rich plaque, will almost certainly have been com-
One of the more exciting developments in the closing
years of the last century was the development of endovas-
cular stents. Stents provide exciting options for the man-
agement of peripheral vascular disease (PVD). The
complications and many comorbidities of PVD often make
surgical management challenging. Endovascular stents
offer a viable alternative to surgery and perhaps in the
future a less invasive treatment method with few compli-
cations. Amongst the current limitations of endovascular
stents for atherosclerosis and PVD are the overall expense
of the device, the complexity of deployment, the need for
good “anchoring” to the diseased vessel wall, and the sub-
sequent development of restenosis. There is a paucity of
details regarding the morphologic findings in explanted
peripheral stents from humans with PVD. In this issue,
Inoue et al discuss the pathogenetic heterogeneity of in-
stent lesion formation in human peripheral arterial disease.
The paper offers some insights into the development and
progression of restenosis in peripheral stents.
Life expectancy has increased worldwide, particularly
in affluent Western societies, with individuals of more than
age 85 years now comprising the most rapidly growing
segment of the population of the United States and
Canada.1 With this increase in the aging population and
the prevalence of atherosclerotic disease, the need for vas-
cular interventions will continue to grow. Unfortunately,
this age group also has many associated comorbidities,
which make major surgical procedures hazardous.
Endovascular devices, with shorter procedure times and
shorter hospitalizations, will clearly become more attrac-
tive as a primary means of treatment. The current main-
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pressed by the stent struts. At 2 weeks and more, a new
cellular intima, comprised predominantly of cells with the
features of smooth muscle cells, begins to appear.
Thrombi show evidence of organization, and the presence
of fresh thrombi beyond this time suggests the ongoing
formation of thrombi. At 30 days and beyond, the chronic
inflammatory cell reaction slowly increases.
At longer terms after stent deployment (30 days and
beyond), new intimal tissue growth is seen around stent
struts. The thickness of this new intima increases with time
and with the degree of medial damage. In many stents,
this new intimal proliferation is circumferential and fairly
uniform in thickness. The more superficial parts of the
lesion (adjacent to the lumen) are generally more cellular,
and the matrix is richer in mucopolysaccharides. In stents
deployed for more than 30 days, the vessel shows a similar
degree of reaction as compared with vessels that undergo
angioplasty alone.3
In animal-based (porcine) restenosis model studies,
the changes have been more clearly defined and are as fol-
lows. At 24 hours, there is evidence of fibrin, platelets,
monocytes, and polymorphonuclear leukocytes.4 At 7
days, thrombus shows features of organization and is asso-
ciated with macrophages and the proliferation of cells with
features of smooth muscle cells. Neutrophils are still pres-
ent. At 2 to 4 weeks, proliferating smooth muscle type
cells are the dominant cells. Occasional mononuclear
inflammatory cells are present. Seldom is there a sugges-
tion of multinucleate giant cell reaction to the stent mate-
rial. The deeper layers gradually become less cellular, with
more collagen and less matrix, and the superficial layers
remain cellular and matrix rich.
There is a difference in the vascular reaction to stent-
ing in animal models when compared with the human
results. The more significant neointimal reaction in exper-
imental animals is related to the greater likelihood of
injury to the otherwise histologically healthy vessel wall
(medial injury-compression or tears and damage to
endothelial cells).
In the Inoue study in this issue of the Journal, the
authors have shown in human peripheral vascular stent
explants, the presence of a neointima, which is more cel-
lular and matrix rich in its superficial layer and less cellu-
lar, collagen rich, and matrix poor, in the deeper parts.
They did not find any significant macrophage reaction to
the strut material, attesting to its nonreactivity. There is no
comment in the study about damage to the media.
However, compression of the media is seen in some of the
illustrative material and is an “accepted” part of the effects
of angioplasty and stenting.
The finding of greater PCNA-based staining in the
superficial part of this neointima is not surprising and is in
keeping with the greater cellularity and cell proliferation in
this zone, as compared with the other zones (the deeper
part of the neointima). The authors suggest this pattern is
a result of a unique combination of mechanisms and
believe that the data in this study show two different
pathogenetic processes in different zones, contributing to
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“in-stent lesion formation at the same time.” In my opin-
ion, it is more likely that both zones are part of a contin-
uum of change. A similar pattern of neointima maturation
is seen in both angioplasty vessels and bypass grafts, with
a more cellular composition near the lumen overlying
mature, mainly acellular intima.5 In addition, the deeper
parts may show increased amounts of elastin and some
new vessels.
LIMITATIONS
This study is a retrospective analyses of a small num-
ber (n = 5) of human explants. The study has the limita-
tions inherent in any such study because materials are
available only as and when they have to be explanted, and
therefore, a timeframe for change is difficult to establish.
This is in contrast to experimental studies, where tissues
are harvested on a planned basis. Cause and effect are
therefore more difficult to evaluate and measure.
Correlations with clinical sequelae thus have to be made
with care and with use of the human explant data in the
context of the known sequence of events reported in
experimental studies. One must, of course, keep in mind
that experimental data may or may not always be repre-
sentative of the human situation. The development of a
neointima is a critical event, with the potential to lead to
the failure of these devices. As such, efforts need to be
made to study it in greater detail. This study by Ianoe et
al is a step in this direction. 
FUTURE
Many efforts have been made to reduce neointima for-
mation. Some investigators have used stents made radioac-
tive with 32P ion implantation techniques, with reported
reduction of neointimal growth. However, this technique
appears to be associated with poor endothelialization at 3
months and incomplete healing.6 Other approaches
include the stent-based delivery of sirolimus, an immuno-
suppressive agent, which results in dose-related inhibition
of intimal reaction.7 Yet another technique being consid-
ered is endothelial cell seeding after stenting. In the
future, stem cells may be used for the same purpose. Such
advancements will hopefully increase further the success of
endovascular stenting and promote its wider use.
SUMMARY
Endovascular repair of PVD has the potential for sig-
nificantly reducing morbidity and mortality rates. These
reductions may be dramatic.1 The option of a less invasive
procedure, coupled with shorter in-hospital and recovery
times, make this an attractive proposition for patients,
physicians, and hospital administrators. At this time, these
procedures still have problems that need to be addressed,
one of the more significant being neointima formation, a
reaction potentially “lethal” to the device. All current indi-
cators point to the increasing use of this procedure with
continually improving results. The publication of human
data, especially with good clinical/pathologic correlates,
will more rapidly help refine the devices.
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